Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company held the 8th meeting of the 6th Board of Directors on November 28, 2025, and the 6th extraordinary general meeting of shareholders on December 17, 2025, to review and approve the proposal on the use of part of the idle raised funds and own funds for cash management. The Company and its subsidiaries are authorized to use no more than RMB 1.1 billion of idle raised funds (including oversubscribed funds) and own funds for cash management, with raised funds not exceeding RMB 800 million and own funds not exceeding RMB 300 million. The cash management period is within 12 months from the date of approval by the shareholders' meeting, and the above limits can be used in a rolling manner within the effective period. For specific details, please refer to the announcement on the use of part of the idle raised funds and own funds for cash management disclosed by the Company on November 29, 2025, on designated information disclosure media and the Giant Tide Information Network (www.cninfo.com.cn) (Announcement No.: 2025-120).
- The redemption situation of cash management products using part of the idle raised funds and own funds is as follows: